Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Temporary Authorization for Use (ATU) to Avelumab for Treatment of Adult Patients With Metastatic Merkel Cell Carcinoma (mMCC)

Trial Profile

Temporary Authorization for Use (ATU) to Avelumab for Treatment of Adult Patients With Metastatic Merkel Cell Carcinoma (mMCC)

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 11 Dec 2018

At a glance

  • Drugs Avelumab (Primary)
  • Indications Merkel cell carcinoma
  • Focus Adverse reactions; Expanded access; Therapeutic Use
  • Sponsors Merck KGaA
  • Most Recent Events

    • 05 Jun 2018 The expanded access program is ongoing but will close in 2018 (US closed in April 2017) with regulatory approval in multiple countries as per results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 29 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top